文献速递神经肿瘤

RNA剪接作为脑膜瘤DNA甲基化分组的生物标志物和表型驱动因素

RNA splicing as a biomarker and phenotypic driver of meningioma DNA-methylation groups.
PubMed 文献 · Neuro Oncol · 2024-01-01

本研究利用486例脑膜瘤样本的RNA测序数据,对应3个DNA甲基化分组(merlin完整型、免疫富集型和高有丝分裂型),并进行体外细胞系实验。研究发现组间RNA剪接改变,其中个别剪接事件与高有丝分裂型相关并能预测肿瘤复发和患者预后,且可准确预测DNA甲基化分类。SRSF1上调驱动剪接改变,针对NASP和MFF的剪接转换反义寡核苷酸为RNA治疗设计提供依据。

要点

  • RNA剪接改变可区分脑膜瘤DNA甲基化分组并预测复发与预后。
  • 高有丝分裂型脑膜瘤中SRSF1上调驱动RNA剪接改变。
  • 针对NASP和MFF的剪接转换反义寡核苷酸为治疗提供思路。

核心结论

  • RNA剪接是脑膜瘤表型的重要驱动因素,可用于预后判断并作为潜在治疗靶点。

研究设计与样本

  • 利用486例脑膜瘤样本的RNA测序数据,对应3个DNA甲基化分组(merlin完整型、免疫富集型和高有丝分裂型),并进行人脑膜瘤细胞系体外实验。

主要发现

  • 鉴定出脑膜瘤DNA甲基化分组间的RNA剪接改变,包括与高有丝分裂型相关并能预测肿瘤复发和患者总生存的个别剪接事件。
  • 汇编了一组可基于RNA测序数据准确预测DNA甲基化分类的剪接事件,并在患者样本和脑膜瘤细胞系中用逆转录聚合酶链反应(RT-PCR)验证。
  • 鉴定出位于RNA剪接事件上游的RNA结合蛋白和剪接因子改变,包括高有丝分裂型脑膜瘤中SRSF1上调,并显示其驱动选择性RNA剪接改变。
  • 设计靶向高有丝分裂型脑膜瘤中观察到的NASP和MFF RNA剪接改变的剪接转换反义寡核苷酸,为RNA治疗设计提供依据。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Advances in our understanding of the molecular biology of meningiomas have led to significant gains in the ability to predict patient prognosis and tumor recurrence and to identify novel targets for therapeutic design. Specifically, classification of meningiomas based on DNA methylation has greatly improved our ability to risk stratify patients, however new questions have arisen in terms of the underlying impact these DNA-methylation signatures have on meningioma biology. METHODS: This study utilizes RNA-sequencing data from 486 meningioma samples corresponding to 3 meningioma DNA-methylation groups (merlin-intact, immune-enriched, and hypermitotic), followed by in vitro experiments utilizing human meningioma cell lines. RESULTS: We identify alterations in RNA splicing between meningioma DNA-methylation groups including individual splicing events that correlate with hypermitotic meningiomas and predict tumor recurrence and overall patient prognosis and compile a set of splicing events that can accurately predict DNA-methylation classification based on RNA-seq data. Furthermore, we validate these events using reverse transcription polymerase chain reaction (RT-PCR) in patient samples and meningioma cell lines. Additionally, we identify alterations in RNA-binding proteins and splicing factors that lie upstream of RNA splicing events, including upregulation of SRSF1 in hypermitotic meningiomas which we show drives alternative RNA splicing changes. Finally, we design splice-switching antisense oligonucleotides to target RNA splicing changes in NASP and MFF observed in hypermitotic meningiomas, providing a rationale for RNA-based therapeutic design. CONCLUSIONS: RNA splicing is an important driver of meningioma phenotypes that can be useful in prognosticating patients and as a potential exploit for therapeutic vulnerabilities.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Leclair NK, Choudury A, Chen WC, et al. RNA splicing as a biomarker and phenotypic driver of meningioma DNA-methylation groups. Neuro Oncol. 2024. PMID: 39093629. doi:10.1093/neuonc/noae150

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。